ACTIVE LEARNING TEMPLATES TherapeuTic procedure A7
Medication
STUDENT NA ME _____________________________________
MEDICATION __________________________________________________________________________ REVIEW MODULE CHAPTER ___________
CAT EGO RY CL ASS ______________________________________________________________________
ACTIVE LEARNING TEMPLATE:
PURPOSE OF MEDICATION
Expected Pharmacological Action
Complications
Contraindications/Precautions
Interactions
Medication Administration
Evaluation of Medication Effectiveness
Therapeutic Use
Nursing Interventions
Client Education
Alexis Jimenez
Montelukast
Anti-Inflammatory Drugs/Leukotrine Modifiers
Leukotrine modifiers work to suppress the
effect of leukotrines. Decrease inflammation
by preventing the activation of leukotrines.
Route: PO Oral/chewable tablets
and oral granules.
Sprinkle over or mix in
applesauce, carrots, rice,
icecream or place directly under
the tongue.
Do not take again for 24 hours.
Interact with other drugs. Clients taking phenobarbital,
rifampin or phenytoin require higher doses of montelukast.
Do not give leukotrine modifiers for acute asthma
excerbations or status asthmatics because of the time it
takes for drug to take effect. Use in caution with clients who
have severe asthma because of higher level efficacy than
other drugs.
No serious untoward side effects occur. Slight risk of
adverse neuropsychiatric symptoms such as suicidal
thoughts/behaviors.
Used to treat patients with allergic rhinitis,
asthma and excercise induced
bronchospasm.
-Mild analgesics are required for
clients who experience
headache after administration.
-Monitor respirations, rate/depth.
-Monitor/assess lung sounds
-Observe lips and fingernials
cyanosis s/s
Patient can breathe more easily.
-Report any headaches after
administration.
-Encourage use of OTC
analgesic medications.
-Monitor clients for any
behaviroal changes indicating
Sucidial Ideation or depression.
References:
Vallerand, A.H. & Sanoski, C.A. (2019). Davis’s drug guide for nurses (16th Ed.). Philadelphia, PA: Elsevier.
